S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

Vaso News Headlines (OTCMKTS:VASO)

$0.03
0.00 (0.00 %)
(As of 02/17/2020 02:28 PM ET)
Today's Range
$0.02
Now: $0.03
$0.03
50-Day Range
$0.02
MA: $0.03
$0.03
52-Week Range
$0.01
Now: $0.03
$0.07
Volume7,510 shs
Average Volume60,184 shs
Market Capitalization$5.48 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8

Headlines

Vaso (OTCMKTS VASO) News Headlines

Source:
DateHeadline
Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market 2020 AstraZeneca PlcGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market 2020 AstraZeneca Plc
www.marketwatch.com - February 12 at 1:14 PM
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market - Uncertainty PrevailsVaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market - Uncertainty Prevails
www.marketwatch.com - February 6 at 8:59 AM
Global Non-invasive Monitoring Devices Market Anticipated to Mask at a CAGR 5.6% by 2027|Omron Corporation, Vaso CorporationGlobal Non-invasive Monitoring Devices Market Anticipated to Mask at a CAGR 5.6% by 2027|Omron Corporation, Vaso Corporation
www.marketwatch.com - January 24 at 9:57 AM
Taqueria Company and Gonzz Steak Burger bring more choices to Evansville mallTaqueria Company and Gonz'z Steak Burger bring more choices to Evansville mall
www.msn.com - January 18 at 5:49 PM
How Visine Eye Drops In The Mouth Can Kill, Here Are Two CasesHow Visine Eye Drops In The Mouth Can Kill, Here Are Two Cases
www.forbes.com - January 18 at 5:49 PM
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market With Moderate CAGR in Forecast Period 2019 to 2026Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market With Moderate CAGR in Forecast Period 2019 to 2026
www.marketwatch.com - January 9 at 6:35 AM
Global Blood: Beware Of This Key Investment Risk As Voxelotor Enters CommercializationGlobal Blood: Beware Of This Key Investment Risk As Voxelotor Enters Commercialization
seekingalpha.com - December 2 at 6:22 PM
CRISPR Therapeutics: Progress In Treatment Of Blood Disorders Using CRISPR/Cas9 Looks Highly PromisingCRISPR Therapeutics: Progress In Treatment Of Blood Disorders Using CRISPR/Cas9 Looks Highly Promising
seekingalpha.com - December 2 at 1:21 PM
Vertex, CRISPRs Gene Editing Drug Shows Positive Early DataVertex, CRISPR's Gene Editing Drug Shows Positive Early Data
finance.yahoo.com - November 20 at 1:00 PM
FDA approves first targeted therapy to treat patients with painful complication of sickle cell diseaseFDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
finance.yahoo.com - November 15 at 7:12 PM
Vaso Corporation Reports Financial Results for Third Quarter 2019Vaso Corporation Reports Financial Results for Third Quarter 2019
finance.yahoo.com - November 14 at 1:07 PM
Why Banda Los Sebastianes New No. 1 Song Will Keep Them Striving for MoreWhy Banda Los Sebastianes' New No. 1 Song Will Keep Them 'Striving for More'
www.msn.com - November 8 at 10:35 PM
Vaso-Occlusive Crisis Pipeline Insight Report 2019 - ResearchAndMarkets.comVaso-Occlusive Crisis Pipeline Insight Report 2019 - ResearchAndMarkets.com
www.businesswire.com - October 23 at 12:55 PM
Vaso Actives Claims Prompt SEC to Step InVaso Active's Claims Prompt SEC to Step In
www.thestreet.com - October 13 at 12:57 AM
Vaso Corporation (VASO)Vaso Corporation (VASO)
finance.yahoo.com - August 14 at 9:27 PM
Vaso Corporation Reports Financial Results for Second Quarter 2019Vaso Corporation Reports Financial Results for Second Quarter 2019
finance.yahoo.com - August 14 at 10:48 AM
GlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell DiseaseGlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
www.marketwatch.com - August 3 at 10:00 AM
GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2019 Results - Earnings Call TranscriptGlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 2 at 9:47 PM
How Europe’s winemakers take on climate changeHow Europe’s winemakers take on climate change
www.ft.com - August 2 at 9:47 PM
Global Blood Therapeutics: A Promising Biotech Pick In 2019Global Blood Therapeutics: A Promising Biotech Pick In 2019
seekingalpha.com - July 29 at 5:00 PM
Novartis Accelerated Review Sets Up A Potential Catalyst For FDA ApprovalNovartis' Accelerated Review Sets Up A Potential Catalyst For FDA Approval
seekingalpha.com - July 25 at 6:34 PM
Novartis (NVS) Crizanlizumab Gets Priority Review From FDANovartis' (NVS) Crizanlizumab Gets Priority Review From FDA
finance.yahoo.com - July 16 at 4:13 PM
Novartis International AG: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)Novartis International AG: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
www.finanznachrichten.de - July 16 at 11:11 AM
Global Blood Therapeutics Data Falls On Deaf Ears, But Massive Potential Exists With Accelerated Approval PathwayGlobal Blood Therapeutics' Data Falls On Deaf Ears, But Massive Potential Exists With Accelerated Approval Pathway
seekingalpha.com - June 18 at 9:41 PM
Vaso Corporation Reports Financial Results for First Quarter 2019Vaso Corporation Reports Financial Results for First Quarter 2019
finance.yahoo.com - May 15 at 11:14 AM
Karolinska Developments portfolio company Modus Therapeutics announces results from a Phase 2 study of sevuparin in patients with sickle cell diseaseKarolinska Development's portfolio company Modus Therapeutics announces results from a Phase 2 study of sevuparin in patients with sickle cell disease
www.globenewswire.com - May 13 at 11:28 AM
Vaso-Occlusive Crisis Associated with Sickle Cell Disease - Pipeline Insight, 2019 - ResearchAndMarkets.comVaso-Occlusive Crisis Associated with Sickle Cell Disease - Pipeline Insight, 2019 - ResearchAndMarkets.com
www.businesswire.com - May 8 at 4:26 PM
GlycoMimetics, Inc.Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell DiseaseGlycoMimetics, Inc.Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
www.marketwatch.com - May 6 at 4:24 PM
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year for 2018Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year for 2018
finance.yahoo.com - April 15 at 9:17 AM
Karolinska Developments portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparinKarolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin
globenewswire.com - January 8 at 10:53 AM
FDA tags Novartis crizanlizumab a Breakthrough Therapy for sickle cell pain crisesFDA tags Novartis' crizanlizumab a Breakthrough Therapy for sickle cell pain crises
seekingalpha.com - January 8 at 10:53 AM
Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Insight Report 2018 - ResearchAndMarkets.comGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Insight Report 2018 - ResearchAndMarkets.com
www.marketwatch.com - December 19 at 3:52 PM
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel